The National Institute for Health and Clinical Excellence (NICE) has today published final guidance on the use of pemetrexed (Alimta) for the treatment of locally advanced or metastatic non-small-cell lung cancer. The guidance does not recommend the use of this drug and means that the appeal by Eli Lilly and Co. against the recommendations contained in the Final Appraisal Determination (FAD) has not been successful.